---
id: bronchiectasis-exacerbation
condition: Bronchiectasis Exacerbation
aliases: [bronchiectasis flare, acute bronchiectasis exacerbation, infective bronchiectasis exacerbation]
icd10: [J47.0, J47.1, J47.9]
esi: 3
time_to_harm: "< 24 hours (if severe respiratory compromise)"
category: respiratory
track: tier1
sources:
  - type: guideline
    ref: "2019 ERS Guidelines for the Management of Adult Bronchiectasis. Eur Respir J. 2017;50(3):1700629."
  - type: guideline
    ref: "2024 ATS/ERS Clinical Practice Guideline for Bronchiectasis in Adults. Am J Respir Crit Care Med. 2024."
  - type: review
    ref: "Chalmers JD, et al. Bronchiectasis. Nat Rev Dis Primers. 2018;4:45."
last_updated: "2026-03-01"
compiled_by: agent
risk_tier: B
validation:
  automated_consistency_check: null
  dose_range_validator: null
  unit_normalization_check: null
  cross_file_consistency_check: null
  citation_presence_check: null
  duplicate_content_check: null
  outlier_detection_flag: clear
  schema_version: "2.0"
  provenance_links: []
---
# Bronchiectasis Exacerbation

## Recognition

**Definition of exacerbation (>= 3 of the following for >= 48 hours):**
- Increased cough frequency or severity
- Increased sputum volume or change in consistency
- Increased sputum purulence
- Increased dyspnea or decreased exercise tolerance
- Fatigue or malaise
- Hemoptysis (new or worsened)

**Presentation:**
- Chronic productive cough at baseline, now worsened
- Increased volume and purulence of sputum (often foul-smelling if anaerobic)
- Fever (suggests superinfection)
- Hemoptysis — ranges from blood-streaked sputum to massive hemoptysis
- Wheezing, crackles on auscultation
- Hypoxemia in severe exacerbations

**Common pathogens:**
- H. influenzae (most common in non-CF bronchiectasis)
- Pseudomonas aeruginosa (chronic colonization, worse prognosis)
- S. pneumoniae, Moraxella catarrhalis
- S. aureus (especially with ABPA or CF)
- Nontuberculous mycobacteria (MAC) — insidious, consider if treatment-refractory
- Aspergillus (ABPA — associated with CF and severe bronchiectasis)

## Critical Actions

| Action | Target |
|---|---|
| Sputum culture | Before antibiotics |
| Antibiotic initiation | < 2 hours |
| O2 supplementation | Immediate if SpO2 < 92% |
| Assess for massive hemoptysis | At presentation |

1. **Sputum culture BEFORE antibiotics** — essential for guiding therapy; many patients have resistant organisms (especially Pseudomonas)
2. **Start empiric antibiotics** based on prior culture history if available:
   - No prior Pseudomonas: amoxicillin-clavulanate 875/125 mg PO BID or doxycycline 100 mg PO BID
   - Prior Pseudomonas: ciprofloxacin 750 mg PO BID or IV antipseudomonal (piperacillin-tazobactam 4.5 g IV q6h or cefepime 2 g IV q8h)
3. **Airway clearance:** Aggressive chest physiotherapy, oscillating positive expiratory pressure device, postural drainage, nebulized hypertonic saline 7% (mucolytic)
4. **Bronchodilators:** Albuterol 2.5 mg nebulized q4-6h (if bronchospasm)
5. **Supplemental O2** if SpO2 < 92%
6. **Hemoptysis management:** If massive (> 100 mL/24h) — see pulmonary hemorrhage protocol; interventional radiology for bronchial artery embolization

## Differential Diagnosis

- **COPD exacerbation** — overlapping features; bronchiectasis distinguished by CT with dilated airways, lack of smoking history in many
- **Pneumonia** — focal consolidation vs diffuse bronchiectatic changes
- **Tuberculosis** — weight loss, night sweats, upper lobe disease, AFB positive
- **NTM infection (MAC)** — indolent course, middle lobe/lingula predilection, AFB culture positive
- **Allergic bronchopulmonary aspergillosis (ABPA)** — high IgE, eosinophilia, Aspergillus-specific IgE/IgG, central bronchiectasis
- **Lung cancer** — hemoptysis, weight loss, new mass on imaging

## Workup

- **Sputum culture and sensitivity:** Including AFB if NTM on differential. Collect before antibiotics.
- **CXR:** Tramline shadows, ring shadows, mucous plugging, new consolidation
- **CT chest (HRCT):** Signet ring sign (bronchial diameter > adjacent artery), lack of tapering, cystic changes — confirmatory for bronchiectasis; assess extent and new changes
- **Labs:** CBC (leukocytosis), CRP, BMP, ABG (if severe)
- **Pulmonary function tests (outpatient):** FEV1 for baseline and trend
- **If first presentation or treatment-refractory:** Investigate underlying cause — immunoglobulins (hypogammaglobulinemia), sweat chloride (CF), alpha-1 antitrypsin, Aspergillus-specific IgE (ABPA), ciliary biopsy (PCD)

## Treatment

### Antibiotic Therapy
- **Mild (outpatient):**
  - No Pseudomonas history: amoxicillin-clavulanate 875/125 mg PO BID x 14 days or doxycycline 100 mg PO BID x 14 days
  - Pseudomonas history: ciprofloxacin 750 mg PO BID x 14 days
- **Moderate-Severe (inpatient):**
  - Empiric: piperacillin-tazobactam 4.5 g IV q6h or cefepime 2 g IV q8h
  - Pseudomonas confirmed: antipseudomonal beta-lactam + aminoglycoside (tobramycin 5-7 mg/kg IV daily)
  - Duration: 14 days (minimum)
- **MRSA:** Add vancomycin 15-20 mg/kg IV q8-12h or linezolid 600 mg IV q12h

### Airway Clearance (Critical Adjunct)
- Chest physiotherapy with postural drainage 2-4x daily
- Oscillating PEP device (Flutter, Acapella)
- Nebulized hypertonic saline 7% (4 mL) BID — mucolytic, improves sputum clearance
- Nebulized dornase alfa — CF bronchiectasis ONLY (harmful in non-CF bronchiectasis)

### Hemoptysis
- Mild: continue antibiotics, tranexamic acid 1 g PO TID
- Moderate-massive: bronchial artery embolization (IR); emergent intubation if airway compromise
- Surgical resection for recurrent hemoptysis from localized disease

### Chronic Management (Outpatient)
- Inhaled tobramycin 300 mg BID or nebulized aztreonam — for chronic Pseudomonas (eradication or suppression)
- Azithromycin 250 mg PO 3x/week — reduces exacerbation frequency (macrolide immunomodulation)
- Annual influenza and pneumococcal vaccination
- Pulmonary rehabilitation

## Disposition

- **ICU admission:** Respiratory failure, massive hemoptysis, sepsis
- **Inpatient admission:** IV antibiotics required (Pseudomonas, failed oral therapy), severe exacerbation with hypoxemia, hemoptysis requiring monitoring
- **Outpatient:** Mild exacerbation in patient with good baseline function, reliable follow-up, oral antibiotic appropriate
- **Pulmonology follow-up:** All patients with recurrent exacerbations (>= 3/year), Pseudomonas colonization, declining FEV1

## Pitfalls

1. **Not obtaining sputum culture before starting antibiotics.** Bronchiectasis patients often harbor resistant organisms (especially Pseudomonas). Empiric antibiotics may be inappropriate, and prior culture data is essential for guiding therapy. Always try to collect sputum before the first dose.

2. **Treating bronchiectasis exacerbation like simple COPD exacerbation.** Bronchiectasis requires longer antibiotic courses (14 days vs 5-7 for COPD), different empiric coverage (Pseudomonas), and aggressive airway clearance. Short courses of azithromycin are insufficient.

3. **Using dornase alfa (Pulmozyme) in non-CF bronchiectasis.** Dornase alfa improves outcomes in CF but has been shown to WORSEN outcomes in non-CF bronchiectasis. Use nebulized hypertonic saline instead for mucolysis.

4. **Ignoring airway clearance therapy.** Antibiotics alone are insufficient for bronchiectasis exacerbations. Sputum stasis perpetuates infection. Chest physiotherapy, postural drainage, and mucolytic nebulizers are essential adjuncts.

5. **Failing to investigate the underlying cause in new diagnoses.** Bronchiectasis is not a diagnosis — it is a structural consequence of an underlying condition. Workup for immunodeficiency, CF, ABPA, NTM, alpha-1 antitrypsin deficiency, and primary ciliary dyskinesia should be pursued.
